{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:57:38Z","timestamp":1790521058978,"version":"4.1.0"},"reference-count":52,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100015303","name":"Otsuka Pharmaceutical Development and Commercialization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015303","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Atten Disord"],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Attention-deficit\/hyperactivity disorder (ADHD) is characterized by core symptoms of inattention, hyperactivity, and impulsivity that are persistent and can interfere with daily functioning. Centanafadine is a norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) and cental nervous symstem simulant recently FDA approved for the treatment of ADHD in both adult and pediatric patients. This secondary analysis explores the efficacy of centanafadine for the treatment of ADHD core symptoms as measured by the clinical scales, Conners 3\u2013Parent Short and Conners 3\u2013Self-Report Short, in a children and adolescents over 6\u2009weeks of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Two phase 3, multicenter, randomized, double-blind, placebo-controlled trials were conducted in the United States and Canada (children: NCT05428033; adolescents: NCT05257265).This analysis included children (6\u201312\u2009years) or adolescents (13\u201317\u2009years) with a primary diagnosis of ADHD randomized (1:1:1) to receive once-daily extended-release high-dose centanafadine, low-dose centanafadine, or placebo for 6\u2009weeks without initial titration. Secondary outcomes presented here include the change from baseline in Conners 3\u2013Parent Short and Conners 3\u2013Self-Report Short Inattention and Hyperactivity\/Impulsivity T-scores over Weeks 1 to 6 analyzed using a mixed-effect model for repeated measures and a prespecified integrated analysis of clinically meaningful within-patient change for the Conners 3\u2013Parent Short analyzed via a Cochran\u2013Mantel\u2013Haenszel test. Low-dose centanafadine did not meet the primary endpoint; therefore, low-dose data have been excluded from this presentation, and subsequent presented\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      -values are not controlled for multiplicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In children (mean age 9\u2009years, 59% male) and adolescents (mean age 15\u2009years, 59% male), centanafadine showed separation from placebo as early as Week 1 (the first postbaseline time point), with significant improvements in inattention at each study timepoint over Weeks 1 to 6 as reported by both caregivers (Conners 3\u2013Parent Short) and adolescents (Conner 3\u2013Self-Report Short). Hyperactivity\/Impulsivity was also significantly improved with centanafadine in children and adolescents at each week from Weeks 1 to 6 based on the Conners 3\u2013Parent Short T-scores and at Weeks 4, 5, and 6 for the Conners 3\u2013Self-Report Short. Compared to placebo, children treated with centanafadine had a 55% higher chance, and adolescents had a 65% higher chance of experiencing clinically meaningful within-patient change in inattention and a 48% and 46% higher chance in hyperactivity\/impulsivity, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>Centanafadine was efficacious in children and adolescents with ADHD, providing robust caregiver-reported and self-reported improvements when compared with placebo in the core symptoms of inattention, hyperactivity, and impulsivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>ClinicalTrials.gov identifiers: NCT05257265 and NCT05428033.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10870547261483444","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:34:57Z","timestamp":1790228097000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinically Meaningful Within-Patient Change in Core Attention-Deficit\/Hyperactivity Disorder Symptoms in Children and Adolescents Treated With Centanafadine: Results From Two Phase 3 Randomized Clinical Trials"],"prefix":"10.1177","author":[{"given":"Caroline L.","family":"Ward","sequence":"first","affiliation":[{"name":"Otsuka Pharmaceutical Development &amp; Commercialization, Inc., Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"Oberdhan","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development &amp; Commercialization, Inc., Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Jin","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development &amp; Commercialization, Inc., Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisa","family":"Skubiak","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development &amp; Commercialization, Inc., Princeton, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4355-8691","authenticated-orcid":false,"given":"Judy","family":"van Stralen","sequence":"additional","affiliation":[{"name":"Center for Pediatric Excellence, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory W.","family":"Mattingly","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5782-7891","authenticated-orcid":false,"given":"Ann C.","family":"Childress","sequence":"additional","affiliation":[{"name":"Center for Psychiatry and Behavioral Medicine, Inc., Las Vegas, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001575"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acap.2011.10.003"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30269-4"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.4135\/9781412984010"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s44192-022-00030-1"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/15374416.2024.2335625"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-5-14"},{"key":"e_1_3_4_10_1","unstructured":"DuPaul G. J. Langberg J. M. (2015). Educational impairments in children with ADHD. In Barkley R. A. (Ed.) Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment (4th ed.). The Guilford Press."},{"key":"e_1_3_4_11_1","volume-title":"ADHD rating scale-5 for children and adolescents: Checklists, norms, and clinical interpretation","author":"DuPaul G.","year":"2016","unstructured":"DuPaul G., Power T., Anastopoulos A., Reid R. (2016). ADHD rating scale-5 for children and adolescents: Checklists, norms, and clinical interpretation. The Guilford Press."},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.01.022"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-018-0070-0"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106275"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105085"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.10662"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(21)00395-3"},{"key":"e_1_3_4_18_1","author":"Guy W.","year":"1976","unstructured":"Guy W. (1976). ECDEU Assessment Manual for Psychopharmacology. U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs.","journal-title":"ECDEU Assessment Manual for Psychopharmacology"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2010.11.005"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-018-0438-2"},{"key":"e_1_3_4_21_1","doi-asserted-by":"crossref","unstructured":"Leffa D. T. Caye A. Rohde L. A. (2022). ADHD in children and adults: Diagnosis and prognosis. In Current Topics in Behavioral Neurosciences (pp. 1\u201318). Springer International Publishing. https:\/\/doi.org\/10.1007\/7854_2022_329","DOI":"10.1007\/7854_2022_329"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/00099228221111246"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221140008"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107940"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001404"},{"key":"e_1_3_4_26_1","volume-title":"Attention-Deficit\/Hyperactivity Disorder (ADHD)","author":"National Institute of Mental Health.","year":"2024","unstructured":"National Institute of Mental Health. (2024). .Attention-Deficit\/Hyperactivity Disorder (ADHD). https:\/\/www.nimh.nih.gov\/sites\/default\/files\/documents\/health\/publications\/adhd-2024.pdf"},{"key":"e_1_3_4_27_1","unstructured":"Oberdhan D. Wilens T. E. Ward C. L. Stralen J. v. Jin N. Skubiak T. Childress A. C. (n.d.). In Executive functioning in pediatric patients with attention-deficit\/hyperactivity disorder: Analysis of Conners 3 and exit survey responses. APSARD 2025 Annual Meeting San Diego CA USA."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33004-1"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-021-01064-9"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/1034912X.2019.1596226"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-020-02542-y"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-023-01456-1"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0135"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013510699"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13070966"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05305whi"},{"key":"e_1_3_4_37_1","unstructured":"SIMTRIYO\u00ae (centanafadine) extended-release capsules [prescribing information]. Princeton NJ: Otsuka America Pharmaceutical Inc.; 2026."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0280131"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087054714530782"},{"issue":"1","key":"e_1_3_4_40_1","first-page":"154","article-title":"Brief report: Daily living skills are impaired in adolescents with ADHD","volume":"10","author":"Tamm L.","year":"2024","unstructured":"Tamm L., Freehling E. M., Saunders T. A., Duncan A. (2024). Brief report: Daily living skills are impaired in adolescents with ADHD. Evidence-Based Practice in Child and Adolescent Mental Health, 10(1), 154\u2013161. https:\/\/doi.org\/10.1080\/23794925.2024.2324768","journal-title":"Evidence-Based Practice in Child and Adolescent Mental Health"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2010.03.008"},{"key":"e_1_3_4_42_1","unstructured":"Turkoglu O. Ward C. L. Childress A. C. Wilens T. E. Jin N. Skubiak T. van Stralen J. Arnold V. K. (2026). Long-Term Safety and Efficacy of Centanafadine in Children and Adolescents With ADHD: Results From a Phase 3 Open-Label Extension Study. APSARD San Diego CA USA."},{"key":"e_1_3_4_43_1","volume-title":"American Professional Society of ADHD and Related Disorders (APSARD) 2026 Annual Conference","author":"Turkoglu O.","year":"2026","unstructured":"Turkoglu O., Ward C. L., Jin N., Skubiak T., Childress A. C., van Stralen J., Arnold V. K. (2026, January 15-18). Long-term safety of centanafadine in children and adolescents with ADHD: Results from a phase 3 open-label extension study [Poster presentation]. American Professional Society of ADHD and Related Disorders (APSARD) 2026 Annual Conference, San Diego, CA."},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.06.005"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12402-016-0199-0"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1177\/10870547231155438"},{"key":"e_1_3_4_47_1","article-title":"Centanafadine for attention-deficit\/hyperactivity disorder in adolescents: A randomized clinical trial","author":"Ward C. L.","year":"2025","unstructured":"Ward C. L., Childress A. C., Jin N., Turkoglu O., Skubiak T., Wilens T. E. (2025). Centanafadine for attention-deficit\/hyperactivity disorder in adolescents: A randomized clinical trial. Journal of the American Academy of Child & Adolescent Psychiatry. Advance online publication. https:\/\/doi.org\/10.1016\/j.jaac.2025.06.023","journal-title":"Journal of the American Academy of Child & Adolescent Psychiatry"},{"key":"e_1_3_4_48_1","volume-title":"Long-term changes in ADHD symptoms assessed by the Conners 3\u2013parent short: Results from a phase 3 open-label extension study of centanafadine in children and adolescents with ADHD","author":"Ward C. L.","year":"2026","unstructured":"Ward C. L., Childress A. C., Wilens T. E., Oberdhan D., Jin N., Skubiak T., Stralen J. v., Arnold V. K. (2026). Long-term changes in ADHD symptoms assessed by the Conners 3\u2013parent short: Results from a phase 3 open-label extension study of centanafadine in children and adolescents with ADHD. APSARD, San Diego, CA, USA."},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1542\/pedsos.2024-000349"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0241-3"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S242084"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/10445463261441745"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2023.110751"}],"container-title":["Journal of Attention Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547261483444","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10870547261483444","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10870547261483444","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:28:22Z","timestamp":1790519302000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10870547261483444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":52,"alternative-id":["10.1177\/10870547261483444"],"URL":"https:\/\/doi.org\/10.1177\/10870547261483444","relation":{},"ISSN":["1087-0547","1557-1246"],"issn-type":[{"value":"1087-0547","type":"print"},{"value":"1557-1246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"10870547261483444"}}